Related by context. All words. (Click for frequent words.) 71 IIIB 65 IIIA NSCLC 61 IIb 59 IIIa 58 stage IIIB 58 IIIb 58 IV NSCLC 56 stage IIIA 56 Stage IIIA 55 IV melanoma 55 unresectable stage 55 Stage IIB 54 IVa 54 International Prognostic Scoring 54 histologically confirmed 53 pT3 53 NYHA 53 Soft Tissue Sarcoma 52 completely resected 52 CLL SLL 52 Stage IIIB 52 Glioblastoma Multiforme 51 severe oral mucositis 51 urothelial carcinoma 51 T1a 51 haematologic 51 â ‰ ¥ 51 T1c 51 IV metastatic melanoma 51 cervical carcinoma 51 dacarbazine DTIC 51 pT2 51 cutaneous squamous cell carcinoma 51 stage IIIb 51 fluoropyrimidine 51 plus 5-FU/LV 51 receptor tyrosine kinase inhibitor 51 IIa 51 nonmetastatic 51 moderately emetogenic 50 squamous cell carcinoma SCC 50 Bayer HealthCare Onyx Pharmaceuticals 50 Follicular Lymphoma 50 Pressure Transducer 50 PEG IFN 50 Ibritumomab Tiuxetan 50 gastrointestinal toxicities 50 unresectable 50 cytoreductive nephrectomy 50 metastatic renal 50 NHDP phase 50 anemia neutropenia 50 Acute Myeloid Leukaemia AML 50 liposomal amphotericin B 50 metastatic malignant 50 under NHDP Phase 49 mRCC 49 Stage IIIb 49 SBIR Contract 49 recurrent metastatic 49 leukemia AML 49 hematologic toxicity 49 Sezary syndrome 49 hepatorenal syndrome 49 histological subtype 49 recurrent NSCLC 49 histologic subtype 49 glioblastoma GBM 49 metastatic bladder 49 follicular lymphoma FL 49 NYHA Class III 49 preoperative PSA 49 cough dyspnea 49 total thyroidectomy 49 gemcitabine carboplatin 49 follicular thyroid cancer 49 neutropaenia 49 resectable 49 grade cervical intraepithelial 49 lymphadenectomy 49 non hematologic toxicities 49 Hataf 49 metastatic gastric 49 JT# 49 multicentric 49 Multiple Myeloma MM 49 locoregional 49 postoperative chemotherapy 49 anaplastic astrocytomas 49 NYHA Class II 49 extranodal 48 Fludarabine 48 metastatic malignant melanoma 48 biopsy Gleason 48 surgically resectable 48 Topoisomerase 48 surgically resected 48 myelodysplastic syndrome MDS 48 IIIC 48 Pegylated Liposomal Doxorubicin 48 chemoradiation therapy 48 GORE TAG Device 48 Anaplastic 48 extracapsular extension 48 metastatic GIST 48 mycosis fungoides 48 prostate carcinoma 48 Accelerated Approval 48 Cinacalcet HCl 48 pain palliation 48 1 diabetes T1D 48 Pemetrexed 48 histologies 48 BRITE Star 48 esophageal carcinoma 48 NYHA Class 48 aspartate aminotransferase AST 48 paclitaxel carboplatin 48 REVIVE Diabetes 48 erlotinib Tarceva ® 48 papillary renal cell carcinoma 48 IIb IV 48 gastroduodenal 48 seminal vesicle invasion 48 WGS Block 48 mildly symptomatic 48 biliary tract cancer 48 CTOL 48 Cutaneous T 48 stage IIIb IV 48 diabetes mellitus DM 48 HYCAMTIN 48 cytologically confirmed 48 gemcitabine Gemzar ® 48 II 48 FDG PET imaging 48 vWD 48 Class1 48 Peripheral Arterial 48 Squamous Cell Carcinoma 48 advanced medullary thyroid 47 KRAS wild 47 intra arterial 47 nonsmall cell lung cancer 47 cisplatin vinorelbine 47 underwent resection 47 Retreatment 47 IV 47 thymoma 47 oral treprostinil 47 5-FU/LV 47 medically inoperable 47 Receptor Antagonists 47 DLTs 47 B#.# [001] 47 cisplatin chemotherapy 47 Astrocytoma 47 mCRPC 47 Critical Limb Ischemia CLI 47 LITENING 47 ZACTIMA 47 inotropic therapy 47 urothelial 47 IIIc 47 Kellgren Lawrence 47 steroid refractory GvHD 47 refractory metastatic 47 OPEVAL 47 NHDP Phase 47 recurrent colorectal cancer 47 intratumoral 47 ACCLAIM COPD 47 MKC# MT 47 nonmetastatic prostate cancer 47 Hematologic 47 CIN2 + 47 advanced hepatocellular carcinoma 47 lymph node involvement 47 Temsirolimus 47 pegylated interferon alfa 2b 47 creatine kinase CK 47 Adjuvant Treatment 47 relapsing remitting MS RRMS 47 confirmatory Phase 47 neutropenia febrile neutropenia 47 FOLPI 47 MELAS 47 TNM staging 47 Acute Myelogenous Leukemia AML 47 Accelerated Partial Breast Irradiation 47 de novo AML 47 Familial Hypercholesterolemia 47 AATD 47 TIA EIA 47 5 fluorouracil leucovorin 46 B Cell Lymphoma 46 colorectal metastases 46 assessing T DM1 46 ALCM 46 CRp 46 resectable pancreatic cancer 46 medullary thyroid carcinoma 46 Infantry Carrier 46 FluCAM arm 46 intraepithelial neoplasia 46 BrahMos Block 46 Metastatic Renal Cell Carcinoma 46 colorectal adenoma 46 ovarian carcinoma 46 Cyclophosphamide 46 metastatic renal cell carcinoma 46 ara C 46 conformal radiotherapy 46 Pralatrexate 46 relapsed MM 46 Relapsing Remitting Multiple Sclerosis 46 intravenous recombinant 46 Kahalalide F 46 Enhanced Combat Helmet 46 glycopeptide 46 Efficacy Trial 46 AJCC 46 pancreatic carcinoma 46 Myelodysplastic Syndrome 46 Balloon Catheters 46 biventricular 46 Immunohistochemical staining 46 #A# #A# 46 Chronic Lymphocytic Leukemia 46 papillary RCC 46 curative resection 46 Hormone Refractory Prostate Cancer 46 Common Toxicity Criteria 46 adriamycin 46 GVAX Pancreas Vaccine 46 PROSTVAC ® 46 Infusion Reactions Severe 46 Platinol ® 46 astrocytomas 46 Small Diameter Bomb SDB 46 basal cell carcinoma BCC 46 procainamide 46 Dose Ranging Study 46 MW Teesta 46 RTCA DO #B 46 ovarian cancer chronic hepatitis 46 platinum refractory 46 Mucopolysaccharidosis 46 CTCAE 46 ASIA Impairment 46 Epratuzumab 46 Hatf VI 46 capsular polysaccharide 46 bronchial hyperresponsiveness 46 Histologic 46 refractory AML 46 astrocytoma 46 anaplastic astrocytoma 46 ABVD 46 occlusion PAO 46 lymphocytosis 46 transitional cell carcinoma 46 Thrombolysis 46 T1 T2 46 5alpha reductase 46 unfavorable cytogenetics 46 Interferon Alfa 46 squamous 46 MIL DTL 46 prospective multicenter study 46 TORISEL 46 visceral metastases 46 Prolongs Survival 46 diabetes mellitus T2DM 46 RAS mutations 46 #Gy 46 neoplasia CIN 46 prostate cancer PCa 46 IVB 46 gastric adenocarcinoma 46 demethylation agents 46 MTR# 46 post thrombotic syndrome 46 ECOG PS 46 refractory ovarian cancer 46 C #A Globemaster 45 baseline LDH 45 situ CIS 45 PCa 45 metastatic RCC 45 Tumor Necrosis Factor 45 2A 2B 45 visilizumab 45 pelvic lymphadenectomy 45 grade squamous intraepithelial 45 F/A-#E/F aircraft 45 lymph node metastasis 45 CD# CD# 45 HIRF 45 Unresectable 45 neoplasias 45 HBeAg positive chronic hepatitis 45 Randomized Phase 45 ballistic missile Agni 45 soft tissue sarcomas 45 multicenter randomized controlled 45 HCV Genotype 45 intraperitoneally 45 LymphoStat B belimumab 45 Inspection Authorization 45 endometrioid 45 anterior lumbar interbody fusion 45 bavituximab monotherapy trial 45 PAOD 45 MIL DTL # 45 neuroendocrine cancers 45 recurrent glioblastoma multiforme 45 FOLFOX4 45 MPGN 45 Hepatocellular Carcinoma HCC 45 Thermal Weapon Sights 45 homozygotes 45 System IPSS 45 Xelox 45 pediatric malignancies 45 Lenalidomide 45 macrolide antibiotic 45 PSMA ADC 45 MVax 45 alpha1 antitrypsin deficiency 45 AH #D Block 45 Contact Resistance LLCR 45 renal pelvis 45 preserved LVEF 45 variceal hemorrhage 45 Plus STAARVISC TM 45 refractory chronic lymphocytic 45 bleomycin 45 SDD phase 45 Alkaline Phosphatase 45 relapsed acute myelogenous 45 HLA DR4 45 Angiotensin Converting Enzyme 45 hepatocellular carcinomas 45 adverse cytogenetics 45 azacytidine 45 hematopoietic cancers 45 1 TES Cartosat 45 Plus Ribavirin 45 Paul Steigleder 45 medullary thyroid cancer 45 Iluvien TM 45 LS5 45 underwent surgical resection 45 Mammographic 45 NAVISTAR R 45 metastatic colorectal 45 initiate multicenter 45 #E# [003] 45 tenecteplase 45 Small Tactical Unmanned 45 Apolipoprotein 45 APACHE II 45 argatroban 45 Patients Treated With 45 SAGD Phase 45 Rapid Virologic Response 45 DEB# 45 albiglutide currently 45 elevated troponin 45 Adenomas 45 Omacetaxine 45 Eli Lilly Gemzar 45 Yondelis ® 45 patientswith 45 trial evaluating Prochymal 45 urinary N telopeptide 45 paclitaxel poliglumex 45 Doxil ® 45 Lenocta 45 piperacillin tazobactam 45 receiving Vectibix monotherapy 45 Station CROWS 45 Papillary 45 HuMax EGFr 45 ASTM E# [001] 45 Orbital Sciences Taurus 45 intestinal metaplasia 44 null mice 44 III 44 CIN3 44 mycophenolate mofetil 44 cancer mCRC 44 Hatf VI Shaheen 44 nodular BCC 44 Pivotal Phase II 44 monoclonal antibody conjugated 44 EDSS score 44 STRIDE PD 44 castrate resistant 44 mucinous 44 EHEDG 44 multicentre phase 44 Radiofrequency ablation 44 complement inhibitor eculizumab 44 HBeAg negative 44 T2 T3 44 ER CHOP 44 galiximab 44 neoadjuvant chemotherapy 44 p# biomarker 44 Chronic Myelogenous Leukemia CML 44 Subtype 44 neoadjuvant 44 Adjuvant chemotherapy 44 gallium nitrate 44 refractory colorectal cancer 44 Guided Missile 44 non squamous 44 dasatinib Sprycel 44 T3 T4 44 microbiologically evaluable 44 MARPOL Annex 44 Niemann Pick type 44 COPERNICUS 44 Mycophenolate Mofetil 44 metastatic androgen independent 44 sodium glucose cotransporter 44 liver resection 44 peritoneal carcinomatosis 44 lymphovascular invasion 44 RAF kinase 44 cholangiocarcinoma 44 Initiated Phase 44 Metastatic Prostate Cancer 44 vinorelbine tartrate 44 NCAA Divsion 44 NSABP B 44 treat chronic sinusitis 44 symptomatic DVT 44 ATIRCM 44 Myelodysplastic Syndrome MDS 44 Leucovorin 44 Congenital Emphysema 44 Myelodysplastic Syndromes 44 Lymphocytic 44 IRS 1D Resourcesat 44 Unified Parkinson Disease 44 unresectable Stage III 44 Radezolid 44 prostate cancer CaP 44 endothelin receptor antagonists 44 MW Barh 44 Capecitabine 44 malignant ovarian 44 S1 S# [001] 44 cutaneous melanoma 44 procollagen 44 IIa clinical 44 Forodesine 44 biliary stones 44 EBRT 44 androgen deprivation 44 Tumor Response 44 metastatic relapsed 44 CG# oncolytic virus 44 Soft Tissue Sarcomas 44 Delafloxacin 44 tumors GIST 44 nodal dissection 44 JESD# [001] 44 radiotherapy RT 44 ß blockers 44 PREZISTA r arm 44 AV 8B 44 debulking surgery 44 alpha1 44 VATS lobectomy 44 WCMD 44 Gemcitabine 44 recurrent endometrial cancer 44 APS #C 44 undergoing radical cystectomy 44 Embolic 44 idarubicin 44 Mitomycin C 44 pulmonary metastases 44 CDAD Clostridium difficile 44 endometrial adenocarcinoma 44 Cutaneous Melanoma 44 Cardiotoxicity 44 AMVISC ® AMVISC ® 44 Janus kinase 44 Mil Std 44 failure NYHA 44 Platinol ® cisplatin 44 gefitinib Iressa 44 mCi 44 V/# 44 Evidence Therapeutic Level 44 Metastatic Pancreatic Cancer 44 antiangiogenic agent 44 Epirubicin 44 ALSFRS R 44 HER2 positive metastatic breast 44 4mg/kg 44 Ispinesib SB # 44 subscores 44 Metastatic breast cancer 44 immunomodulatory therapy 44 GW# [003] 44 fallopian tube carcinoma 44 Neutropenia 44 Histological 44 Bosentan 44 C 5Bs 44 Level TRL 44 Cl IV 44 urothelial bladder cancer 44 CTEPH 44 Esophageal 44 DEF STAN 44 sodium thiosulfate STS 44 Fontan procedure 44 B.2 44 atypical hemolytic uremic syndrome 44 nodal metastasis 44 Metastatic Melanoma 44 pericardial effusion 44 ATSM 44 Bioequivalence 44 ENVG 44 localized prostate 44 achieved CCyR 44 recurrent glioblastoma 44 Prognostic significance 44 chronic thromboembolic pulmonary 44 gadolinium enhancing 43 CYT# potent vascular disrupting 43 myocardial revascularization 43 Fibromyalgia Impact Questionnaire 43 V0 43 #A.# [003] 43 UPDRS 43 Xanafide 43 neuroendocrine carcinoma 43 Vascugel ® 43 Factor VIIa 43 Initiate Phase 43 adjuvant radiotherapy 43 miconazole Lauriad ® 43 Subphase 43 suppl #S 43 subthreshold 43 peritumoral brain edema 43 prognostic variables 43 lymph node metastases 43 chemo immunotherapy 43 Deadlinepix 43 metastatic pancreatic 43 Nodular 43 Peginterferon Alfa 2a 43 tumor necrosis 43 weekly subcutaneous injections 43 AST ALT 43 dimeglumine 43 seminoma 43 MJU 43 Aflibercept 43 advanced pancreatic neuroendocrine 43 Estrogen Receptor 43 ^ Tc 43 including eniluracil ADH 43 Abstract Number 43 C1 C2 43 Randomized phase 43 Ozarelix 43 D1 D2 43 Sejjil 43 Decitabine 43 antiarrhythmic drugs 43 inhaled AAT 43 Ziprasidone 43 Hurthle cell 43 Neuvenge 43 multiple endocrine neoplasia 43 FNPT II MCC 43 Subscale 43 variant allele 43 transurethral 43 Disinfection Byproducts Rule 43 CORE Phase 43 steroid refractory ulcerative 43 BRAF V#E 43 Pooled Analysis 43 essential thrombocythemia ET 43 Category 6a 43 ipsilateral breast 43 polyposis 43 pancreatic prostate 43 recombinant Factor 43 #A #A [001] 43 megohms 43 CsA 43 Submarine Launched 43 epithelial ovarian 43 unresectable locally advanced 43 palliative radiotherapy 43 B1 B2 B3 43 renal carcinoma 43 multidetector 43 REALiS SX7 Mark 43 parathyroid carcinoma 43 neoadjuvant therapy 43 BEXXAR Therapeutic Regimen 43 Coronary Artery Bypass Graft 43 fentanyl citrate C 43 M#V 43 AH 1W 43 Surgical resection 43 ACE Inhibitors 43 operable breast cancer 43 Metastatic 43 Prospective Randomized 43 Commences Phase 43 Trapeza CDO 43 GH deficiency 43 Shellgel TM injectable viscoelastic 43 secondary hyperparathyroidism SHPT 43 Diabetic Retinopathy DR 43 metabotropic glutamate receptors 43 pulmonary hypertension PH 43 Fibromyalgia syndrome 43 Chemokine Receptor 43 R armodafinil Tablets 43 LRIP 43 Malignant Melanoma 43 TRUS 43 malignant ascites 43 Resection 43 advanced unresectable 43 Pelvic Organ Prolapse 43 von Willebrand disease 43 FAA DO #B 43 acute cholecystitis 43 #ug [002] 43 neoadjuvant treatment 43 colorectal liver metastases 43 MACQUARIE DEVELOPMENT CAPITAL 43 T2DM 43 MDCT angiography 43 Phospholipase 43 radical cystectomy 43 DU# [002] 43 Input Voltage 43 epithelial tumors 43 AN/APG-# radar 43 tuberous sclerosis TS 43 III EGFRvIII 43 #C [005] 43 myelofibrosis polycythemia vera 43 fluticasone propionate FP 43 tumor xenograft models 43 XFP optics 43 BY FRANK RADOSEVICH 43 #HT [001] 43 Sulfonylurea 43 prostate cancer HRPC 43 hematologic abnormalities 43 heFH 43 Fitch Rates Wells Fargo 43 beta lactamase inhibitor 43 Interferon alfa 43 AIM #D 43 MoxDuo R 43 NuroPro PD 43 mitomycin C 43 F FLT 43 MALT lymphoma 43 Symptom Checklist 43 Confirmatory 43 Epidermal Growth Factor Receptor 43 activating mutation 43 #SD [001] 43 Secretory 43 Non Alcoholic Steatohepatitis 43 Electro Optical Targeting 43 TVID 43 4F 43 Interferon gamma 43 EGFR HER2 43 sorafenib Nexavar ® 43 paronychial inflammation 43 bladder carcinoma 43 bronchogenic carcinoma 43 clinicopathological features 43 TRAIL R1 43 Advanced Renal Cell 43 collagenous colitis 43 AGM #E 43 EN #-# [002] 43 IL2 43 refractory anemia RA 43 hypophosphatemia 43 hormone refractory metastatic prostate 43 Ceplene/IL-2 43 Glioblastoma Multiforme GBM 43 Proxinium TM 43 hemorrhagic cystitis 43 F FDG PET 43 Castration Resistant Prostate Cancer 43 Trabectedin 43 ALN HPN 43 multicenter phase 43 Orally administered 43 #A# [005] 43 Class IIIb 43 carboxypeptidase 43 bi ventricular pacing 43 distant metastases 42 selective endothelin receptor antagonist 42 Spitfire Mk 42 labial herpes 42 Fe Ti 42 Chemoradiation 42 MVA HPV IL2 42 benign prostatic hypertrophy BPH 42 renal cell carcinoma 42 gadobutrol 42 BRCA deficient 42 apolipoprotein B 42 node dissection 42 transcranial Doppler ultrasound 42 paveway II Plus 42 GSF Development Driller 42 Extended Range ER 42 concurrent chemoradiation 42 Chronic Sinusitis 42 Ischemic 42 neuropathic pain metabolic diseases 42 nasopharyngeal carcinoma 42 proliferator activated receptor 42 ENGAGE AF TIMI 42 Cytotoxic 42 Tomahawk Block 42 benzothiazole 42 Squamous 42 Relapsed Refractory 42 PIMCO Municipal Income 42 evaluating Prochymal 42 selective adenosine 42 thermally optimized 42 TLR antagonist 42 Full Flight Simulator 42 Virtus Plus 42 JAGM 42 Main Outcome Measure 42 Bevacizumab 42 urothelial cancer 42 coronary stenosis 42 VII VIII 42 univariate analysis 42 IIa trials 42 Dose Escalation Study 42 AESA radars 42 paragangliomas 42 targeting miR 42 aspirin clopidogrel 42 NSCIF Division 42 elevated LDH 42 Bohol Irrigation 42 Pivotal Phase 42 MALD J 42 fallopian tube cancers 42 biologic DMARD 42 metastatic lymph nodes 42 Common Remotely Operated Weapon 42 gastroesophageal junction 42 Liraglutide Effect 42 Technical Specification 42 James Layug 42 HAIPE 42 MEND CABG II 42 Amgen Neulasta R 42 Rapeseed Rajasthan #/#.# # 42 C1 C2 C3 42 Cholinesterase Inhibitors 42 clinically evaluable CE 42 II SBIR 42 Raytheon APG 42 BENICAR HCT 42 #BASE 42 CKD Stage 42 Small Diameter Bombs 42 mineralocorticoid receptor 42 Pharmacokinetics PK 42 T#C [001] 42 HDL cholesterol HDL 42 IRBMs 42 glatiramer acetate GA 42 Antiviral Therapy 42 Occlusive Disease 42 VII IX 42 GSTP1 42 Biliary 42 UH 1Y 42 locoregional disease 42 VIII 42 Evidence Prognostic Level 42 EQ 5D 42 Myelofibrosis 42 LH RH 42 Hypertrophy 42 FXIII 42 Patients Receiving 42 Systemic Sclerosis 42 Severity Level 42 neoadjuvant chemoradiotherapy 42 Silodosin 42 GEH Generation 42 Adjuvant Chemotherapy 42 diarrhea predominant irritable 42 III • dhusty@news-press.com 42 BMC2 42 mycophenolate 42 Patriot PAC 42 TEVAR 42 Novel Inhibitor 42 NTx 42 isoprostane 42 AN/APG-# 42 6D 42 refractory NSCLC 42 Cloretazine 42 BCG refractory 42 Vekacia R 42 Hepatocellular Carcinoma 42 Tyrosine Kinase Inhibitors 42 ACTIQ ® 42 NC1 42 systemic lupus erythematosus 42 severe gastroparesis 42 F UTP 42 EA 6B 42 endobronchial 42 #,# ton KDX 42 Dasatinib 42 metastatic adenocarcinoma 42 Telatinib 42 Geographic Atrophy 42 symptomatic benign prostatic 42 HER pathway 42 Carcinoma 42 Nilotinib 42 myeloproliferative 42 HIPEC 42 annexin 42 isoenzyme 42 randomized discontinuation 42 histologically proven 42 Hexvix ® 42 succinate dehydrogenase 42 Technology Demonstrator 42 endoscopic resection 42 papillary 42 FPD Link 42 aplastic anemia AA 42 H#.# 42 Hypertriglyceridemia 42 imatinib resistant 42 AMVISC R AMVISC R 42 Chronic lymphocytic leukemia 42 FOLFOX6 42 #B# [002] 42 Parathyroid Hormone 42 RTOG 42 Intermediate Horsemanship 42 oral transmucosal fentanyl citrate 42 xenograft model 42 del 5q 42 #beta hydroxysteroid dehydrogenase 42 adjuvant trastuzumab 42 Oropharyngeal 42 TACE 42 cell chronic lymphocytic 42 CML CP 42 oral Hycamtin 42 humanised antibody 42 FDG-PET/CT 42 Leukemias 42 Adjuvant Therapy 42 Melphalan 42 malignant neoplasm 42 9S 42 CAC2S 42 malignant lymphoma 42 DG# [003] 42 Polymyxin B 42 D#B 42 selective A2A adenosine receptor 42 dose melphalan 42 Compact Flash Type 42 #I [003] 42 DAS# remission 42 thalidomide Thalomid 42 liver histology 42 CIFSouthern Section Division 42 Cell Non Hodgkin 42 Subtypes 42 WOMAC pain 42 smoldering multiple myeloma 42 deoxy 42 colorectal carcinomas 42 NSN #-#-#-# 42 S#W# produced 42 Aurora Kinase 42 Advanced Melanoma 42 vinca alkaloid 42 Resubmission 42 ^ sup #m 42 NS3 42 HIMARS 42 corticosteroid therapy 42 invasive carcinomas 42 Janus Kinase 42 MC #J 42 #u [001] 42 infantile onset 42 AMDR 42 polymyxin B 41 Uptime Institute Tier 41 follicular lymphoma 41 SLEP 41 Carotid 41 familial amyloidotic polyneuropathy FAP 41 Nephrol 41 hepatocellular cancer 41 Motexafin Gadolinium 41 USASA Region 41 Stomatitis 41 KING COBRA 41 Radical prostatectomy 41 anaplastic astrocytoma AA 41 DFSP 41 C3 C4 41 TheraCIM h R3 41 ERBB2 41 VI 41 androgen suppression 41 4A 4B 41 MK# Mod 41 DR4 41 lysosomal enzyme iduronate 41 R#/R# 41 #B.# [002] 41 relapsed ALL 41 Meets Primary Endpoint 41 Cypher Stent 41 maximal treadmill 41 EPC Gen 41 Zevalin consolidation 41 small molecule tyrosine 41 stereotactic radiotherapy 41 VaIN 41 Intravitreal 41 Type IIa 41 adjuvant therapy 41 segmentectomy 41 CMMI maturity 41 HBeAg negative chronic hepatitis 41 Accell TBM 41 ISO# 6B 41 otamixaban 41 austriamicrosystems Introduces 41 Enzastaurin 41 Vortex Flow Meters 41 terlipressin 41 Anti Submarine Warfare ASW 41 bowel syndrome IBS 41 Djambaye 41 LEAGUE DIVISION 41 Technical Specifications 41 Curaxin CBLC# 41 ULA Atlas 41 recurrent glioma 41 myocardial blush 41 Merkava Mk 41 mm diameters 41 Radioimmunotherapy 41 PROTEGE 41 recurrent squamous cell carcinoma 41 Myelodysplastic syndrome 41 resected 41 neuromotor 41 pancreatic adenocarcinoma 41 Luminal 41 primary peritoneal 41 GALNS 41 Hemophilia B